Ambrisentan for sarcoidosis associated pulmonary hypertension

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 28, Issue 2, 2011, Pages 139-145

  Judson, Marc A ^a   Highland, K B ^a   Kwon, S ^a   Donohue, J F ^b   Aris, R ^b   Craft, N ^a   Burt, S ^b   Ford, H J ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Ambrisentan; Pulmonary hypertension; Sarcoidosis; Therapy

Indexed keywords

AMBRISENTAN; BRAIN NATRIURETIC PEPTIDE; SAPHENIC ACID;

ARTICLE; DIFFUSION; DYSPNEA; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; SARCOIDOSIS;

ADULT; ANTIHYPERTENSIVE AGENTS; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUNG; MALE; MIDDLE AGED; NORTH CAROLINA; PHENYLPROPIONATES; PROSPECTIVE STUDIES; PYRIDAZINES; QUALITY OF LIFE; QUESTIONNAIRES; RECOVERY OF FUNCTION; RESPIRATORY FUNCTION TESTS; SARCOIDOSIS; SOUTH CAROLINA; TIME FACTORS; TREATMENT OUTCOME;

EID: 81455131947     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Judson MA. Sarcoidosis: clinical presentation, diagnosis, and approach to treatment. Am J Med Sci 2008; 335: 26-33.
2. Diaz-Guzman E, Farver C, Parambil J, et al. Pulmonary hypertension caused by sarcoidosis. Clin Chest Med 2008; 29: 549-63. (Pubitemid 351778207)
3. Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61: 68-74. (Pubitemid 43106981)
4. Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006; 129: 1246-52.
5. Shorr AF, Helman DL, Davies DB, et al. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005; 25: 783-8. (Pubitemid 40667674)
6. Milman N, Burton CM, Iversen M, et al. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J Heart Lung Transplant 2008; 27: 329-34. (Pubitemid 351375107)
7. Arcasoy SM, Christie JD, Pochettino A, et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest 2001; 120: 873-80. (Pubitemid 32885463)
8. Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003; 124: 922-8. (Pubitemid 37123310)
9. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159: 179-87. (Pubitemid 29036522)
10. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14: 377-81. (Pubitemid 13215050)
11. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991; 85 (Suppl B): 25-31; discussion 33-27.
12. Crapo RO, Morris AH. Standardized single breath normal values for carbon monoxide diffusing capacity. Am Rev Respir Dis 1981; 123: 185-9. (Pubitemid 11146393)
13. Dinakara P, Blumenthal WS, Johnston RF, et al. The effect of anemia on pulmonary diffusing capacity with derivation of a correction equation. Am Rev Respir Dis 1970; 102: 965-9.
14. Hays RD, ed. Rand-36 Health Status Inventory. San Antonio: Pyschological Corporation, 1998.
15. Jones PW. St. George Respiratory Questionnaire Manual. St. George's, Univerity of London, London, England, 2008.
16. Baughman RP, Engel PJ, Taylor L, et al. Survival in sarcoidosis associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest; 138: 1078-85.
17. Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J 2009; 157: 9-21.
18. Rosen Y, Moon S, Huang CT, et al. Granulomatous pulmonary angiitis in sarcoidosis. Arch Pathol Lab Med 1977; 101: 170-4. (Pubitemid 8187786)
19. Takemura T, Matsui Y, Oritsu M, et al. Pulmonary vascular involvement in sarcoidosis: granulomatous angiitis and microangiopathy in transbronchial lung biopsies. Virchows Arch A Pathol Anat Histopathol 1991; 418: 361-8.
20. Westcott JL, DeGraff AC, Jr. Sarcoidosis, hilar adenopathy, and pulmonary artery narrowing. Radiology 1973; 108: 585-6.
21. Preston IR, Klinger JR, Landzberg MJ, et al. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 2001; 120: 866-72. (Pubitemid 32885462)
22. Baughman RP, Engel PJ, Meyer CA, et al. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 108-16. (Pubitemid 47471829)
23. Fisher KA, Serlin DM, Wilson KC, et al. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006; 130: 1481-8. (Pubitemid 44786743)
24. Barnett CF, Bonura EJ, Nathan SD, et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest 2009; 135: 1455-61.
25. Baughman RP, Judson MA, Lower EE, et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26: 110-20.
26. Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 529-35. (Pubitemid 41040298)